Search
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline
Categories: Antidepressive Agents Indicated for Depression, Non-Selective Monoamine Reuptake InhibitorsUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalIt was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
Products: SOGRAS CAPSULA POR 120MG, ORLISTAT MK 120 MG CAPSULASBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigational[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977. … [L39429] Baclofen was investigated for use in alcohol dependence and withdrawal; however, evidence is limited and there is inconsistent evidence to suggest its clinical efficacy in managing alcohol
International brands: Nu-BaclofenProducts: BACLOFEN X 10 MG., Co Baclofen Tablets 10mgBifonazole
go.drugbank.com/drugs/DB04794ApprovedBifonazole is an azole antifungal drug.
Mixtures: . - Salbe + NagelsetCategories: Antifungals for Topical Use, Antifungals for Dermatological UseFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.
Categories: Experimental Unapproved Treatments for COVID-19Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences. … [L34324] On July 28, 2023, the EMA also approved Piflufolastat F18 under the brand name PYLCLARI for primary staging or localizing recurrence of prostate cancer.[L47586]
Brensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.
Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamidePirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalAlthough the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK … [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245154] Notably, none of these agents are approved for use in the treatment of CAD. … [A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.